Professional perspective
Clinical relevance
- Short-term adjunct for gingivitis, and for plaque control in postoperative phases with restricted mechanical oral hygiene
- Professional CHX varnish application for caries prevention in fixed orthodontic appliances and on exposed root surfaces
- Distinguishing CHX mouthwash from CHX varnish: different evidence and recommendation status depending on formulation and indication
- Patient education on staining risk to support compliance
Mechanism of action
Chlorhexidine is a cationic bisbiguanide. It binds to negatively charged structures of the bacterial cell wall; at low concentration it acts bacteriostatically by disrupting membrane function, and at higher concentration bactericidally through cytoplasmic precipitation. Clinically decisive is its pronounced substantivity: CHX adsorbs to enamel, pellicle, restorations, and mucosa, and is slowly released from there over several hours. In an in situ model, CHX remained detectable in saliva for up to seven hours after a single application (García-Caballero et al., 2013).
Side effects and usage notes
The most common effect is extrinsic, reversible staining of tooth hard tissue, restorations, and tongue papillae, intensified by chromogens from food. Other possible effects include taste disturbances and mucosal irritation; hypersensitivity reactions have very rarely been described. If pronounced mucosal reactions, desquamation, or signs of hypersensitivity occur, use should be stopped and professionally evaluated. Contraindications and restrictions on use depend on the specific product and its package information.
Laboratory and clinical studies have described interactions between CHX and anionic toothpaste ingredients such as sodium lauryl sulfate (Barkvoll et al., 1989); even a 30-minute interval between the two left CHX's antiplaque effect significantly reduced, with the interference resolving by around 2 hours. The practical relevance depends on formulation and timing, so product-specific instructions should take precedence.
Comparative evidence suggests a small statistical advantage of 0.2% CHX over 0.12% for plaque inhibition, although its clinical relevance appears limited; no clear difference in gingivitis outcomes has been demonstrated (Berchier et al., 2010). Concentration should therefore be considered together with tolerability, formulation, and the specific indication.
Guideline status
Germany's S3 clinical guideline on caries prevention in permanent teeth (AWMF 083-021) evaluates CHX separately by formulation. For CHX mouthwash used for general caries prevention, no recommendation exists; the guideline draws here on a Cochrane review (Walsh et al., 2015), which found only very low-certainty evidence for a caries-preventive effect versus placebo in children and adolescents. In particular, no additional benefit from chemical plaque inhibitors was found where fluoride prophylaxis was already adequate.
For professionally applied CHX varnish (at least 1 percent CHX), by contrast, the guideline issues its own, separate positive recommendation (evidence-based recommendation 5, modified 2023, Grade 0, ‘may be considered’, strong consensus 13/0/1): during orthodontic treatment with fixed appliances, and on exposed root surfaces. This is based partly on Slot et al. (2011) on root caries, and Lipták et al. (2018), which found a smaller increase in initial carious lesions under CHX varnish in orthodontically treated patients.
The frequently cited evaluation by Slayton et al. (2018), which found no caries-prevention recommendation could be issued for several chemical agents, refers within this guideline explicitly to other substances (including stannous fluoride, cetylpyridinium chloride, CPP-ACP, tricalcium phosphate, nano-hydroxyapatite, arginine, and phenols), not to chlorhexidine, which is addressed in its own section with its own recommendation.
Regulatory status
Various chlorhexidine-containing medicinal products for oral use are available in Germany. Whether a specific product is pharmacy-only, prescription-only, or falls into another product category depends on its authorization, concentration, formulation, and intended purpose. The specific product's labeling is authoritative; for many authorized CHX medicinal products, use is time-limited, and longer-term use should only follow professional consultation, per the relevant product information.
What current evidence does not show
- No recommendation for CHX mouthwash for general, everyday caries prevention; this does not include the specific, professional use of CHX varnish for fixed orthodontic appliances or exposed root surfaces
- No sufficient basis for CHX to replace, rather than supplement, mechanical biofilm control
Evidence summary
What current evidence supports
- High-quality evidence supports additional plaque reduction from CHX mouthwash (James et al., 2017); gingivitis measures can also improve, though the clinical significance of the average effect is limited at mild baseline inflammation
- CHX varnish (at least 1 percent) has a separate, positive guideline recommendation specifically for fixed orthodontic appliances and exposed root surfaces, distinct from the mouthwash evaluation
- CHX's pronounced substantivity is well documented, including direct in situ measurement showing detectability in saliva for up to seven hours after a single application
- Only very low-certainty evidence supports a caries-preventive effect from CHX mouthwash specifically, the basis for its non-recommendation in that use case
- A small, statistically significant advantage of 0.2% over 0.12% CHX for plaque inhibition is documented, though of probably negligible clinical relevance (Berchier et al., 2010)
Why this matters
Understanding that CHX mouthwash and CHX varnish carry separate, formulation-specific evidence and recommendations prevents both under- and overuse: dismissing CHX varnish because mouthwash lacks a caries-prevention recommendation would withhold a guideline-supported option in specific risk situations, while extending mouthwash use into daily long-term caries prevention would extend the product beyond where its evidence and side-effect profile support it.
What remains uncertain
- How consistently the small plaque-inhibition advantage of 0.2% over 0.12% CHX translates into meaningful clinical benefit across different patient populations, given its documented but probably negligible relevance
- Optimal duration and re-treatment intervals for CHX varnish application beyond the specific situations currently addressed by guidelines
James, Worthington, Parnell, et al. (2017): Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database of Systematic Reviews, 2017(3), CD008676. High-quality evidence for additional plaque reduction from CHX mouthwash; gingivitis can also improve, though clinical significance is limited at mild baseline inflammation.
Walsh, Oliveira-Neto, Moore (2015): Chlorhexidine treatment for the prevention of dental caries in children and adolescents. Cochrane Database of Systematic Reviews, 2015(4), CD008457. Only very low-certainty evidence for a caries-preventive effect of CHX versus placebo or no treatment; basis for the guideline's evaluation of CHX rinses.
Berchier, Slot, Van der Weijden (2010): The efficacy of 0.12% chlorhexidine mouthrinse compared with 0.2% on plaque accumulation and periodontal parameters: a systematic review. Journal of Clinical Periodontology, 37(9), 829-839. Small but statistically significant advantage of 0.2% for plaque inhibition, clinical relevance probably negligible; gingivitis data too sparse for comparison.
Supranoto, Slot, Addy, Van der Weijden (2015): The effect of chlorhexidine dentifrice or gel versus chlorhexidine mouthwash on plaque, gingivitis, bleeding and tooth discoloration: a systematic review. International Journal of Dental Hygiene, 13(2), 83-92. Compares formulations and characterizes staining risk as a secondary endpoint.
Barkvoll, Rølla, Svendsen (1989): Interaction between chlorhexidine gluconate and sodium lauryl sulfate in vivo. Journal of Clinical Periodontology, 16(9), 593-595. Documents reduced CHX antiplaque effect even after a 30-minute interval from SLS exposure, resolving by around 2 hours.
García-Caballero, Quintas, Prada-López, Seoane, Donos, Tomás (2013): Chlorhexidine substantivity on salivary flora and plaque-like biofilm: an in situ model. PLoS ONE, 8(12), e83522. In situ model directly measuring CHX substantivity in saliva and biofilm over seven hours after a single application.
